Johnson & Johnson (NYSE:JNJ) issued an update on its FY17 earnings guidance on Thursday morning. The company provided EPS guidance of $7.25 – $7.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.28.
Shares of Johnson & Johnson (NYSE:JNJ) traded up $0.97 on Friday, hitting $145.76. 5,450,270 shares of the stock traded hands, compared to its average volume of 5,920,000. The company has a market capitalization of $391,590.00, a PE ratio of 25.31, a PEG ratio of 2.73 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 12 month low of $110.76 and a 12 month high of $146.42.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The firm had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same quarter last year, the business posted $1.68 earnings per share. The company’s quarterly revenue was up 10.3% on a year-over-year basis. sell-side analysts forecast that Johnson & Johnson will post 7.28 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Stockholders of record on Tuesday, February 27th will be issued a dividend of $0.84 per share. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.31%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 58.33%.
A number of equities analysts have recently commented on the stock. Wells Fargo & Co reiterated an outperform rating and set a $160.00 price target (up previously from $155.00) on shares of Johnson & Johnson in a report on Friday. Vetr raised shares of Johnson & Johnson from a hold rating to a buy rating and set a $150.89 price target for the company in a research note on Thursday. Royal Bank of Canada reaffirmed a buy rating on shares of Johnson & Johnson in a research note on Tuesday. Citigroup lifted their price target on shares of Johnson & Johnson from $140.00 to $149.00 and gave the company a buy rating in a research note on Monday, October 23rd. Finally, Zacks Investment Research downgraded shares of Johnson & Johnson from a buy rating to a hold rating in a research report on Tuesday, December 12th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the company. The company has an average rating of Hold and a consensus target price of $145.94.
A number of institutional investors have recently bought and sold shares of JNJ. Premier Asset Management LLC increased its holdings in shares of Johnson & Johnson by 0.4% in the 2nd quarter. Premier Asset Management LLC now owns 2,749 shares of the company’s stock worth $363,000 after buying an additional 12 shares during the last quarter. LMR Partners LLP bought a new position in shares of Johnson & Johnson during the 2nd quarter valued at $2,784,000. Dupont Capital Management Corp grew its holdings in shares of Johnson & Johnson by 19.5% during the 2nd quarter. Dupont Capital Management Corp now owns 330,122 shares of the company’s stock valued at $43,672,000 after purchasing an additional 53,912 shares during the last quarter. QV Investors Inc. grew its holdings in shares of Johnson & Johnson by 6.7% during the 2nd quarter. QV Investors Inc. now owns 36,565 shares of the company’s stock valued at $4,837,000 after purchasing an additional 2,310 shares during the last quarter. Finally, S. R. Schill & Associates grew its holdings in shares of Johnson & Johnson by 0.4% during the 2nd quarter. S. R. Schill & Associates now owns 10,494 shares of the company’s stock valued at $1,388,000 after purchasing an additional 40 shares during the last quarter. 65.70% of the stock is currently owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This story was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another site, it was copied illegally and reposted in violation of United States and international copyright & trademark law. The original version of this story can be viewed at https://www.dispatchtribunal.com/2018/01/13/johnson-johnson-jnj-updates-fy17-earnings-guidance.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.